Personalizing medicine for autoimmune and inflammatory diseases

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

Asthma phenotypes: the evolution from clinical to molecular approaches

(2012) Sally E Wenzel   NATURE MEDICINE

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Lebrikizumab Treatment in Adults with Asthma

(2011) Jonathan Corren et al.   NEW ENGLAND JOURNAL OF MEDICINE

The intestinal microbiota in inflammatory bowel diseases: time to connect with the host

(2010) Harry Sokol et al.   CURRENT OPINION IN GASTROENTEROLOGY

A Large-Scale, Consortium-Based Genomewide Association Study of Asthma

(2010) Miriam F. Moffatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma

(2009) Prescott G. Woodruff et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Common variants at five new loci associated with early-onset inflammatory bowel disease

(2009) Marcin Imielinski et al.   NATURE GENETICS

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY